Sickle cell anaemia
Sickle cell anaemia, also known as sickle cell disease (SCD), is a genetic disorder
characterized by the production of abnormal haemoglobin, called haemoglobin S (HbS), in
red blood cells. This condition has significant medical, social, and psychological implications
for affected individuals and their families.
1. Genetic Basis
Sickle cell anaemia is inherited in an autosomal recessive manner, meaning that an individual
must inherit two abnormal copies of the haemoglobin gene (one from each parent) to develop
the disease. When both parents carry one abnormal copy and one normal copy of the gene,
they are considered carriers or "carriers" of the disease.
2. Haemoglobin Abnormality
In individuals with sickle cell anaemia, the haemoglobin S (HbS) molecules can change
shape under certain conditions, such as low oxygen levels or dehydration. These altered
haemoglobin molecules cause red blood cells to become rigid and assume a characteristic
crescent or "sickle" shape. This shape change can lead to various health problems.
3. Clinical Manifestations
Sickle cell anaemia is associated with a wide range of clinical manifestations, including:
Pain Crisis: Patients often experience acute, severe pain episodes called vaso-
occlusive crises. These occur when sickle-shaped cells block blood flow, causing
tissue damage and intense pain.
Anaemia: Sickle cell disease can lead to chronic anaemia, characterized by fatigue,
weakness, and pallor due to a decreased number of healthy red blood cells.
Organ Damage: Over time, sickle cells can cause damage to various organs,
including the spleen, liver, kidneys, and lungs. This can result in complications such
as stroke, pulmonary hypertension, and kidney dysfunction.
Infections: Sickle cell patients are at an increased risk of infections, particularly those
caused by encapsulated bacteria like Streptococcus pneumonia.
Delayed Growth: Children with sickle cell anaemia may experience delayed growth
and development.
4. Treatment and Management**
While there is no cure for sickle cell anaemia, advances in medical care have improved the
quality of life for patients. Treatment options include:
Pain Management: Pain crises are managed with pain medications, hydration, and
sometimes blood transfusions.
Hydroxyurea: This medication can help increase the production of fatal
haemoglobin, which reduces the tendency of red blood cells to sickle.
Sickle cell anaemia, also known as sickle cell disease (SCD), is a genetic disorder
characterized by the production of abnormal haemoglobin, called haemoglobin S (HbS), in
red blood cells. This condition has significant medical, social, and psychological implications
for affected individuals and their families.
1. Genetic Basis
Sickle cell anaemia is inherited in an autosomal recessive manner, meaning that an individual
must inherit two abnormal copies of the haemoglobin gene (one from each parent) to develop
the disease. When both parents carry one abnormal copy and one normal copy of the gene,
they are considered carriers or "carriers" of the disease.
2. Haemoglobin Abnormality
In individuals with sickle cell anaemia, the haemoglobin S (HbS) molecules can change
shape under certain conditions, such as low oxygen levels or dehydration. These altered
haemoglobin molecules cause red blood cells to become rigid and assume a characteristic
crescent or "sickle" shape. This shape change can lead to various health problems.
3. Clinical Manifestations
Sickle cell anaemia is associated with a wide range of clinical manifestations, including:
Pain Crisis: Patients often experience acute, severe pain episodes called vaso-
occlusive crises. These occur when sickle-shaped cells block blood flow, causing
tissue damage and intense pain.
Anaemia: Sickle cell disease can lead to chronic anaemia, characterized by fatigue,
weakness, and pallor due to a decreased number of healthy red blood cells.
Organ Damage: Over time, sickle cells can cause damage to various organs,
including the spleen, liver, kidneys, and lungs. This can result in complications such
as stroke, pulmonary hypertension, and kidney dysfunction.
Infections: Sickle cell patients are at an increased risk of infections, particularly those
caused by encapsulated bacteria like Streptococcus pneumonia.
Delayed Growth: Children with sickle cell anaemia may experience delayed growth
and development.
4. Treatment and Management**
While there is no cure for sickle cell anaemia, advances in medical care have improved the
quality of life for patients. Treatment options include:
Pain Management: Pain crises are managed with pain medications, hydration, and
sometimes blood transfusions.
Hydroxyurea: This medication can help increase the production of fatal
haemoglobin, which reduces the tendency of red blood cells to sickle.
